Concord Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $65.2K | Hold |
200
| – | – | 0.01% | 312 |
|
|
2025
Q1 | $54K | Hold |
200
| – | – | 0.01% | 308 |
|
|
2024
Q4 | $47.1K | Hold |
200
| – | – | 0.01% | 339 |
|
|
2024
Q3 | $55K | Hold |
200
| – | – | 0.01% | 324 |
|
|
2024
Q2 | $48.6K | Buy |
+200
| New | +$48.6K | 0.01% | 313 |
|
|
2022
Q3 | – | Sell |
-17
| Closed | -$2K | – | 190 |
|
|
2022
Q2 | $2K | Sell |
17
-111
| -87% | -$13.1K | ﹤0.01% | 985 |
|
|
2022
Q1 | $21K | Buy |
128
+9
| +8% | +$1.48K | 0.01% | 616 |
|
|
2021
Q4 | $20K | Buy |
119
+38
| +47% | +$6.39K | ﹤0.01% | 640 |
|
|
2021
Q3 | $15K | Buy |
81
+31
| +62% | +$5.74K | 0.01% | 415 |
|
|
2021
Q2 | $8K | Buy |
50
+6
| +14% | +$960 | ﹤0.01% | 651 |
|
|
2021
Q1 | $6K | Buy |
+44
| New | +$6K | ﹤0.01% | 642 |
|